Hepatitis B virus reactivation in patients with multiple myeloma receiving bortezomib-containing regimens followed by autologous stem cell transplant

References

• Sun Z, Ming L, Zhu X, et al. Prevention and control of hepatitis B in China. J Med Virol 2002;67:447–450.
   PubMedGoogle Scholar
• Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299–307.
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009;49: S156–S165.
   PubMed Web of Science ®Google Scholar
• Huang B, Li J, Zhou Z, et al. High prevalence of hepatitis B virus infection in multiple myeloma. Leuk Lymphoma 2012;53: 270–274.
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 2009;49:1211–1225.
   PubMed Web of Science ®Google Scholar
• Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209–220.
   PubMed Web of Science ®Google Scholar
• Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004;90: 1306–1311.
   PubMed Web of Science ®Google Scholar
• Papamichalis P, Alexiou A, Boulbou M, et al. Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy. Clin Res Hepatol Gastroenterol 2012;36:84–93.
   Web of Science ®Google Scholar
• Cheng AL, Hsiung CA, Su IJ, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003;37:1320–1328.
   PubMed Web of Science ®Google Scholar
• Hernandez JA, Diloy R, Salat D, et al. Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab. Haematologica 2003;88:ECR22.
   PubMedGoogle Scholar
• Esteve M, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004;53:1363–1365.
   PubMed Web of Science ®Google Scholar
• Lau GK, Liang R, Chiu EK, et al. Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study. Bone Marrow Transplant 1997;19:795–799.
   PubMed Web of Science ®Google Scholar
• Kempinska A, Kwak EJ, Angel JB. Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature. Clin Infect Dis 2005;41:1277–1282.
   PubMed Web of Science ®Google Scholar
• Martin BA, Rowe JM, Kouides PA, et al. Hepatitis B reactivation following allogeneic bone marrow transplantation: case report and review of the literature. Bone Marrow Transplant 1995;15:145–148.
   PubMed Web of Science ®Google Scholar
• Yeo W, Lam KC, Zee B, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 2004;15:1661–1666.
   PubMed Web of Science ®Google Scholar
• Lau GK, Leung YH, Fong DY, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002;99:2324–2330.
   PubMed Web of Science ®Google Scholar
• Hui CK, Bowden S, Jackson K, et al. Clinical significance of intrahepatic hepatitis B virus covalently closed circular DNA in chronic hepatitis B patients who received cytotoxic chemotherapy. Blood 2005;105:2616–2617.
   PubMed Web of Science ®Google Scholar
• Jang JW, Choi JY, Bae SH, et al. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol 2004;41:427–435.
   PubMed Web of Science ®Google Scholar
• Zhong S, Yeo W, Schroder C, et al. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat 2004;11:55–59.
   PubMed Web of Science ®Google Scholar
• Nagamatsu H, Kumashiro R, Itano S, et al. Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCC. Hepatol Res 2003;26:293–301.
   PubMed Web of Science ®Google Scholar
• Dai MS, Wu PF, Lu JJ, et al. Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal study. Support Care Cancer 2004;12:191–196.
   PubMed Web of Science ®Google Scholar
• Shibolet O, Ilan Y, Gillis S, et al. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002;100:391–396.
   PubMed Web of Science ®Google Scholar
• Persico M, De Marino F, Russo GD, et al. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood 2002;99:724–725.
   PubMed Web of Science ®Google Scholar
• Ozguroglu M, Bilici A, Turna H, et la. Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin's lymphoma. Med Oncol 2004;21:67–72.
   PubMed Web of Science ®Google Scholar
• Leaw SJ, Yen CJ, Huang WT, et al. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol 2004;83:270–275.
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004;22:927–934.
   PubMed Web of Science ®Google Scholar
• Yeo W, Ho WM, Hui P, et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat 2004;88:209–215.
   PubMed Web of Science ®Google Scholar
• Jang JW, Choi JY, Bae SH, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006;43:233–240.
   PubMed Web of Science ®Google Scholar
• Lau GK, He ML, Fong DY, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002;36:702–709.
   PubMed Web of Science ®Google Scholar
• Mya DH, Han ST, Linn YC, et al. Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection. Ann Oncol 2012;23:421–426.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Sakuma I, Hashimoto S, et al. Hepatitis B reactivation in a multiple myeloma patient with resolved hepatitis B infection during bortezomib therapy: case report. J Clin Exp Hematop 2012;52:67–69.
   PubMedGoogle Scholar
• Huang H, Cai Q, Lin T, et al. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience. Expert Opin Pharmacother 2009;10:2399–2406.
   PubMed Web of Science ®Google Scholar
• Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008;2:263–283.
   PubMed Web of Science ®Google Scholar
• de Franchis R, Hadengue A, Lau G, et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003;39(Suppl. 1):S3–S25.
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45: 507–539.
   PubMed Web of Science ®Google Scholar
• Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008;57:1–20.
   PubMedGoogle Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167–185.
   PubMed Web of Science ®Google Scholar
• Schütt P, Brandhorst D, Stellberg W, et al. Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leuk Lymphoma 2006;47:1570–1582.
   PubMed Web of Science ®Google Scholar
• Ogawara H, Handa H, Yamazaki T, et al. High Th1/Th2 ratio in patients with multiple myeloma. Leuk Res 2005;29:135–140.
   PubMed Web of Science ®Google Scholar
• Basler M, Lauer C, Beck U, et al. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J Immunol 2009;183:6145–6150.
   PubMed Web of Science ®Google Scholar
• Vogelbacher R, Meister S, Gückel E, et al. Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the rat. Nephrol Dial Transplant 2010;25:3764–3773.
   PubMed Web of Science ®Google Scholar
• Wils EJ, van der Holt B, Broers AE, et al. Insufficient recovery of thymopoiesis predicts for opportunistic infections in allogeneic hematopoietic stem cell transplant recipients. Haematologica 2011; 96:1846–1854.
   PubMed Web of Science ®Google Scholar
• Steingrimsdottir H, Gruber A, Bjorkholm M, et al. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications. Haematologica 2000;85:832–838.
   PubMed Web of Science ®Google Scholar
• Li H, Wu K, Tao K, et al. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology 2012;56:1342–1351.
   PubMed Web of Science ®Google Scholar
• Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Intern 2012;6:531–561.
   PubMed Web of Science ®Google Scholar